Literature DB >> 35488132

Steady-state concentrations of flucloxacillin in porcine vertebral cancellous bone and intervertebral disc following oral and intravenous administration assessed by microdialysis.

Mathias A F Bendtsen1,2,3, Pelle Hanberg4,5,6, Josefine Slater4,5,7, Jakob Hansen4,8, Kristina Öbrink-Hansen4,9, Maiken Stilling4,5,7, Mats Bue4,5,7.   

Abstract

AIMS: Flucloxacillin is a frequently used antibiotic in the treatment of spondylodiscitis. We assessed steady-state concentrations and time above minimal inhibitory concentration (fT > MIC) of flucloxacillin in the intervertebral disc, vertebral cancellous bone, subcutaneous tissue and plasma, after intravenous and oral administration.
METHODS: Sixteen pigs were randomized into two groups; Group Peroral (Group PO) and Group Intravenous (Group IV) received 1 g flucloxacillin every 6 h for 24 h orally or intravenously. Microdialysis was used for sampling in the compartments of interest. A flucloxacillin target of 50% fT > MIC was applied for three MIC targets: 0.125, 0.5 and 2.0 μg/mL.
RESULTS: Intravenous administration resulted in significantly longer fT > MIC for all targets. Target attainment was only reached for the low target of 0.125 μg/mL in Group IV in vertebral cancellous bone, subcutaneous tissue, and plasma (intervertebral disc 47%). In Group IV, mean fT > MIC values in the investigated compartments were in the range of 47-67% of the dosing interval for 0.125 μg/mL, 20-35% for 0.5 μg/mL, and 0-15% for 2.0 μg/mL. In Group PO, mean fT > MIC values for 0.125 μg/mL were in the range of 1-33%. No pigs reached a concentration of 0.5 μg/mL in any of the investigated compartments in Group PO.
CONCLUSION: Administration of 1 g flucloxacillin every 6 h resulted in surprisingly low steady-state fT > MIC after intravenous and oral administration. However, intravenous administration resulted in significantly higher concentrations across compartments compared to oral administration. Sufficient target tissue concentrations for treatment of spondylodiscitis may require a dose increase or alternative dosing regimens.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Animal model; Bone; Flucloxacillin; Infection; Spondylodiscitis

Mesh:

Substances:

Year:  2022        PMID: 35488132     DOI: 10.1007/s00586-022-07208-9

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   2.721


  4 in total

1.  Replacement, reduction and refinement.

Authors:  Paul Flecknell
Journal:  ALTEX       Date:  2002       Impact factor: 6.043

Review 2.  Spondylodiscitis: update on diagnosis and management.

Authors:  Theodore Gouliouris; Sani H Aliyu; Nicholas M Brown
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

Review 3.  Histology and pathology of the human intervertebral disc.

Authors:  Sally Roberts; Helena Evans; Jayesh Trivedi; Janis Menage
Journal:  J Bone Joint Surg Am       Date:  2006-04       Impact factor: 5.284

4.  Single-dose bone pharmacokinetics of vancomycin in a porcine implant-associated osteomyelitis model.

Authors:  Mats Bue; Pelle Hanberg; Janne Koch; Louise Kruse Jensen; Martin Lundorff; Bent Aalbaek; Henrik Elvang Jensen; Kjeld Søballe; Mikkel Tøttrup
Journal:  J Orthop Res       Date:  2017-11-22       Impact factor: 3.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.